170621-85-9

Usage

Uses

Used in Pharmaceutical Industry:
(4-chloro-3-Methoxypyridin-2-yl)Methanol is used as a chemical building block for the synthesis of various pharmaceutical compounds and potential drug candidates due to its versatile functional groups and potential biological activity.
Used in Drug Discovery and Development:
(4-chloro-3-Methoxypyridin-2-yl)Methanol is utilized as a valuable compound in drug discovery and development, contributing to the creation of novel therapeutic agents with potential applications in treating various diseases and conditions.

Upstream product

• 122307-41-9 4-chloro-3-methoxy-2-methylpyridine N-oxide 

Downstream Products

• 335428-53-0 4-chloro-3-methoxypyridine-2-carbaldehyde 
• 503058-51-3 4-chloro-2-chloromethyl-3-methoxypyridine hydrochloride 

Relevant academic research and scientific papers

ISOTOPICALLY SUBSTITUTED PROTON PUMP INHIBITORS

The invention relates to benzimidazoles of Formula (1) and to pharmaceutical compositions comprising these compounds, further to intermediates of Formula (2 and 3).

ISOTOPICALLY SUBSTITUTED PANTOPRAZOLE

The invention relates to compounds of formula 1 and to medicaments comprising these compounds, further to intermediates of formula 2 and 3.

EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS THEREOF

This invention relates to potent selective agonists of the EP4 subtype of prostaglandin E2 receptors, their use or a formulation thereof in the treatment of glaucoma and other conditions, which are related to elevated intraocular pressure in the eye of a patient. This invention further relates to the use of the compounds of this invention for mediating the bone modeling and remodeling processes of the osteoblasts and osteoclasts.

Benzimidazole derivatives

A benzimidazole derivative of formula (1): (wherein R represents a hydrogen atom or a methoxy group, and n is 0 or 1) or a salt thereof; and a medicament containing the same. The compounds of the present invention, due to minimized difference in therapeutic effect between subjects, which difference would otherwise be derived from different CYP2C19 activity from subject to subject, ensure that all patients can enjoy proper therapeutic effects at the same dose of the drug. Also, the compounds of the invention have low risk of drug interaction caused by induction of CYP1A family member enzymes, as well as low risk of development of cancer, and thus is useful as a remedy for peptic ulcer, reliably providing therapeutic effects with safety.

SUBSTITUTED HETEROCYCLIC CARBOXAMIDE ESTERS, THEIR PREPARATION AND THEIR USE AS PHARMACEUTICALS

The invention relates to compounds of the formula I, to a process for their preparation and to their use as pharmaceuticals. The compounds are employed, in particular, as ester prodrugs of prolyl hydroxylase inhibitors for inhibiting collagen biosynthesis and as fibrosuppressive agents